Current treatment for the T2DM is often associated with inadequate control of postprandial hyperglycemia (especially with sulphonylureas, metformin, and thiazolidinediones), weight gain (sulphonylureas, meglitinides, thiazolidinediones, and insulin), and loss of efficacy over time (a problem with all current oral agents). Here, INS is linked to Hyperglycemia.